ASH 2023 | The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the prognostic significance of CD30 expression in the response to brentuximab vedotin for patients with angioimmunoblastic T-cell lymphoma. This study found that CD30 expression did not correlate with response to brentuximab vedotin, nor did it predict which patients would respond favorably to autologous stem cell transplantation (autoSCT). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Salarius, Acrotech, CRISPR, Seagen, Yingli; Research Funding: Pfizer, Ono, Astra Zeneca, Legend, Acrotech, Innate, CRISPR, Seagen, Merck, Drenbio, Yingli; Speakers Bureau: CuraBio, American Society of Hematology, American Society of Transplant and Cellular Therapy.
